The synthesis and characterization of a new water-soluble iminophosphorane ligand TPA=N-C(O)-2BrC(6)H(4) (C,N-IM; TPA = 1,3,5-triaza-7-phosphaadamantane) 1 is reported. Oxidative addition of 1 to Pd(2)(dba)(3) affords the orthopalladated dimer [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) as a mixture of cis and trans isomers (1:1 molar ratio) where the iminophosphorane moeity behaves as a C,N-pincer ligand. By addition of different neutral or monoanionic ligands to 2, the bridging bromide can be cleaved and a variety of hydrophilic or water-soluble mononuclear organometallic palladium(II) complexes of the type [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L-L)] (L-L = acac (3); S(2)CNMe(2) (4); 4,7-Diphenyl-1,10-phenanthrolinedisulfonic acid disodium salt C(12)H(6)N(2)(C(6)H(4)SO(3)Na)(2) (5)); [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L)Br] (L = P(mC(6)H(4)SO(3)Na)(3) (6); P(3-Pyridyl)(3) (7)) and, [Pd(C(6)H(4)(C(O)N=TPA)-2}(TPA)(2)Br] (8) are obtained as single isomers. All new complexes were tested as potential anticancer agents and their cytotoxicity properties were evaluated in vitro against human Jurkat-T acute lymphoblastic leukemia cells, normal T-lymphocytes (PBMC) and DU-145 human prostate cancer cells. Compounds [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) and [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(acac)] 3 (which has been crystallographically characterized) display the higher cytotoxicity against the above mentioned cancer cell lines while being less toxic to normal T-lymphocytes (peripheral blood mononuclear cells: PBMC). In addition, 3 is very toxic to cisplatin resistant Jurkat shBak indicating a cell death pathway that may be different to that of cisplatin. The interaction of 2 and 3 with plasmid (pBR322) DNA is much weaker than that of cisplatin pointing to an alternative biomolecular target for these cytotoxic compounds. All the compounds show an interaction with human serum albumin (HSA) faster than that of cisplatin.
The synthesis and characterization of a new water-soluble n class="Chemical">iminophosphorane ligand TPA=N-C(O)-2BrC(6)H(4) (C,N-IM; TPA = 1,3,5-triaza-7-phosphaadamantane) 1 is reported. Oxidative addition of 1 to Pd(2)(dba)(3) affords the orthopalladated dimer [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) as a mixture of cis and trans isomers (1:1 molar ratio) where the iminophosphorane moeity behaves as a C,N-pincer ligand. By addition of different neutral or monoanionic ligands to 2, the bridging bromide can be cleaved and a variety of hydrophilic or water-soluble mononuclear organometallic palladium(II) complexes of the type [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L-L)] (L-L = acac (3); S(2)CNMe(2) (4); 4,7-Diphenyl-1,10-phenanthrolinedisulfonic acid disodium salt C(12)H(6)N(2)(C(6)H(4)SO(3)Na)(2) (5)); [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L)Br] (L = P(mC(6)H(4)SO(3)Na)(3) (6); P(3-Pyridyl)(3) (7)) and, [Pd(C(6)H(4)(C(O)N=TPA)-2}(TPA)(2)Br] (8) are obtained as single isomers. All new complexes were tested as potential anticancer agents and their cytotoxicity properties were evaluated in vitro against humanJurkat-T acute lymphoblastic leukemia cells, normal T-lymphocytes (PBMC) and DU-145humanprostate cancer cells. Compounds [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) and [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(acac)] 3 (which has been crystallographically characterized) display the higher cytotoxicity against the above mentioned cancer cell lines while being less toxic to normal T-lymphocytes (peripheral blood mononuclear cells: PBMC). In addition, 3 is very toxic to cisplatin resistant Jurkat shBak indicating a cell death pathway that may be different to that of cisplatin. The interaction of 2 and 3 with plasmid (pBR322) DNA is much weaker than that of cisplatin pointing to an alternative biomolecular target for these cytotoxic compounds. All the compounds show an interaction with humanserum albumin (HSA) faster than that of cisplatin.
Authors: A G Quiroga; J M Pérez; I López-Solera; J R Masaguer; A Luque; P Román; A Edwards; C Alonso; C Navarro-Ranninger Journal: J Med Chem Date: 1998-04-23 Impact factor: 7.446
Authors: P Kalaivani; R Prabhakaran; F Dallemer; P Poornima; E Vaishnavi; E Ramachandran; V Vijaya Padma; R Renganathan; K Natarajan Journal: Metallomics Date: 2011-11-03 Impact factor: 4.526
Authors: Christiano M V Barbosa; Carlos R Oliveira; Fábio D Nascimento; Mickaela C M Smith; Daniela M Fausto; Marco Antonio Soufen; Eliana Sena; Ronaldo C Araújo; Ivarne L S Tersariol; Claudia Bincoletto; Antonio C F Caires Journal: Eur J Pharmacol Date: 2006-06-10 Impact factor: 4.432
Authors: Shanta Dhar; Weston L Daniel; David A Giljohann; Chad A Mirkin; Stephen J Lippard Journal: J Am Chem Soc Date: 2009-10-21 Impact factor: 15.419
Authors: Frankline K Keter; Stonard Kanyanda; Sylvester S L Lyantagaye; James Darkwa; D Jasper G Rees; Mervin Meyer Journal: Cancer Chemother Pharmacol Date: 2008-03-19 Impact factor: 3.333
Authors: Elaine G Rodrigues; Luiz S Silva; Daniela M Fausto; Marina S Hayashi; Simone Dreher; Edson L Santos; João B Pesquero; Luiz R Travassos; Antonio C F Caires Journal: Int J Cancer Date: 2003-11-10 Impact factor: 7.396
Authors: Adnan S Abu-Surrah; Talal A K Al-Allaf; Luay J Rashan; Martti Klinga; Markku Leskelä Journal: Eur J Med Chem Date: 2002-11 Impact factor: 6.514
Authors: Malgorzata Frik; Jacob Fernández-Gallardo; Oscar Gonzalo; Víctor Mangas-Sanjuan; Marta González-Alvarez; Alfonso Serrano del Valle; Chunhua Hu; Isabel González-Alvarez; Marival Bermejo; Isabel Marzo; María Contel Journal: J Med Chem Date: 2015-07-22 Impact factor: 7.446
Authors: Malgorzata Frik; Alberto Martínez; Benelita T Elie; Oscar Gonzalo; Daniel Ramírez de Mingo; Mercedes Sanaú; Roberto Sánchez-Delgado; Tanmoy Sadhukha; Swayam Prabha; Joe W Ramos; Isabel Marzo; María Contel Journal: J Med Chem Date: 2014-11-26 Impact factor: 7.446
Authors: Jenna Susan Bleloch; André du Toit; Liezl Gibhard; Serah Kimani; Reyna Deeya Ballim; Minkyu Lee; Angelique Blanckenberg; Selwyn Mapolie; Lubbe Wiesner; Ben Loos; Sharon Prince Journal: Cell Death Discov Date: 2019-01-28